Host acid sphingomyelinase regulates microvascular function not tumor immunity

Monica Garcia-Barros, Daniel Lacorazza, Howard Petrie, Adriana Haimovitz-Friedman, Carlos Cardon-Cardo, Stephen D Nimer, Zvi Fuks, Richard Kolesnick

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Previous studies provided evidence that MCA/129 fibrosarcomas and B16 melanomas grow 2- to 4-fold faster in acid sphingomyelinase (asmase) - deficient mice than in asmase+/+ littermates and are resistant to single-dose irradiation due to inability to mount an apoptotic response in tumor microvascular endothelium. However, others postulated the differences might be associated with a host antitumor immune response in asmase+/+ mice that is not expressed in asmase-/- mice due to phenotypic deficiency in antitumor immunity. The present studies demonstrate that none of the tumor-host combinations displayed the classic criteria of an immunogenic tumor because they lacked endotumoral or peritumoral infiltrates almost entirely. Furthermore, neither MCA/129 fibrosarcoma nor B16 melanoma tumors showed differences in growth or radioresponsiveness when implanted into mutant mouse models (Rag-/- and MEF-/-) lacking functional immune cell [natural killer (NK), NK-T, T, and B cells] populations. Additionally, development and function of B-, T-, and NK-cell populations in asmase -/- mice were normal, indistinguishable from their wild-type littermates. These data provide definitive evidence that MCA/129 fibrosarcomas and B16F1 melanomas do not elicit a host immune response in wild-type mice and that the asmase-/- phenotype is not deficient in antitumor immunity, supporting the notion that the patterns of tumors growth and radiation response are conditionally linked to the ability of the tumor endothelium to undergo ASMase-mediated apoptosis.

Original languageEnglish
Pages (from-to)8285-8291
Number of pages7
JournalCancer Research
Volume64
Issue number22
DOIs
StatePublished - Nov 15 2004
Externally publishedYes

Fingerprint

Sphingomyelin Phosphodiesterase
Immunity
Acids
Fibrosarcoma
Neoplasms
Experimental Melanomas
Natural Killer T-Cells
Endothelium
Growth
Natural Killer Cells
Population
Melanoma
B-Lymphocytes
Radiation
Apoptosis
T-Lymphocytes
Phenotype

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Garcia-Barros, M., Lacorazza, D., Petrie, H., Haimovitz-Friedman, A., Cardon-Cardo, C., Nimer, S. D., ... Kolesnick, R. (2004). Host acid sphingomyelinase regulates microvascular function not tumor immunity. Cancer Research, 64(22), 8285-8291. https://doi.org/10.1158/0008-5472.CAN-04-2715

Host acid sphingomyelinase regulates microvascular function not tumor immunity. / Garcia-Barros, Monica; Lacorazza, Daniel; Petrie, Howard; Haimovitz-Friedman, Adriana; Cardon-Cardo, Carlos; Nimer, Stephen D; Fuks, Zvi; Kolesnick, Richard.

In: Cancer Research, Vol. 64, No. 22, 15.11.2004, p. 8285-8291.

Research output: Contribution to journalArticle

Garcia-Barros, M, Lacorazza, D, Petrie, H, Haimovitz-Friedman, A, Cardon-Cardo, C, Nimer, SD, Fuks, Z & Kolesnick, R 2004, 'Host acid sphingomyelinase regulates microvascular function not tumor immunity', Cancer Research, vol. 64, no. 22, pp. 8285-8291. https://doi.org/10.1158/0008-5472.CAN-04-2715
Garcia-Barros M, Lacorazza D, Petrie H, Haimovitz-Friedman A, Cardon-Cardo C, Nimer SD et al. Host acid sphingomyelinase regulates microvascular function not tumor immunity. Cancer Research. 2004 Nov 15;64(22):8285-8291. https://doi.org/10.1158/0008-5472.CAN-04-2715
Garcia-Barros, Monica ; Lacorazza, Daniel ; Petrie, Howard ; Haimovitz-Friedman, Adriana ; Cardon-Cardo, Carlos ; Nimer, Stephen D ; Fuks, Zvi ; Kolesnick, Richard. / Host acid sphingomyelinase regulates microvascular function not tumor immunity. In: Cancer Research. 2004 ; Vol. 64, No. 22. pp. 8285-8291.
@article{b8c25f76ad7249518c9b4c37352bfd13,
title = "Host acid sphingomyelinase regulates microvascular function not tumor immunity",
abstract = "Previous studies provided evidence that MCA/129 fibrosarcomas and B16 melanomas grow 2- to 4-fold faster in acid sphingomyelinase (asmase) - deficient mice than in asmase+/+ littermates and are resistant to single-dose irradiation due to inability to mount an apoptotic response in tumor microvascular endothelium. However, others postulated the differences might be associated with a host antitumor immune response in asmase+/+ mice that is not expressed in asmase-/- mice due to phenotypic deficiency in antitumor immunity. The present studies demonstrate that none of the tumor-host combinations displayed the classic criteria of an immunogenic tumor because they lacked endotumoral or peritumoral infiltrates almost entirely. Furthermore, neither MCA/129 fibrosarcoma nor B16 melanoma tumors showed differences in growth or radioresponsiveness when implanted into mutant mouse models (Rag-/- and MEF-/-) lacking functional immune cell [natural killer (NK), NK-T, T, and B cells] populations. Additionally, development and function of B-, T-, and NK-cell populations in asmase -/- mice were normal, indistinguishable from their wild-type littermates. These data provide definitive evidence that MCA/129 fibrosarcomas and B16F1 melanomas do not elicit a host immune response in wild-type mice and that the asmase-/- phenotype is not deficient in antitumor immunity, supporting the notion that the patterns of tumors growth and radiation response are conditionally linked to the ability of the tumor endothelium to undergo ASMase-mediated apoptosis.",
author = "Monica Garcia-Barros and Daniel Lacorazza and Howard Petrie and Adriana Haimovitz-Friedman and Carlos Cardon-Cardo and Nimer, {Stephen D} and Zvi Fuks and Richard Kolesnick",
year = "2004",
month = "11",
day = "15",
doi = "10.1158/0008-5472.CAN-04-2715",
language = "English",
volume = "64",
pages = "8285--8291",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "22",

}

TY - JOUR

T1 - Host acid sphingomyelinase regulates microvascular function not tumor immunity

AU - Garcia-Barros, Monica

AU - Lacorazza, Daniel

AU - Petrie, Howard

AU - Haimovitz-Friedman, Adriana

AU - Cardon-Cardo, Carlos

AU - Nimer, Stephen D

AU - Fuks, Zvi

AU - Kolesnick, Richard

PY - 2004/11/15

Y1 - 2004/11/15

N2 - Previous studies provided evidence that MCA/129 fibrosarcomas and B16 melanomas grow 2- to 4-fold faster in acid sphingomyelinase (asmase) - deficient mice than in asmase+/+ littermates and are resistant to single-dose irradiation due to inability to mount an apoptotic response in tumor microvascular endothelium. However, others postulated the differences might be associated with a host antitumor immune response in asmase+/+ mice that is not expressed in asmase-/- mice due to phenotypic deficiency in antitumor immunity. The present studies demonstrate that none of the tumor-host combinations displayed the classic criteria of an immunogenic tumor because they lacked endotumoral or peritumoral infiltrates almost entirely. Furthermore, neither MCA/129 fibrosarcoma nor B16 melanoma tumors showed differences in growth or radioresponsiveness when implanted into mutant mouse models (Rag-/- and MEF-/-) lacking functional immune cell [natural killer (NK), NK-T, T, and B cells] populations. Additionally, development and function of B-, T-, and NK-cell populations in asmase -/- mice were normal, indistinguishable from their wild-type littermates. These data provide definitive evidence that MCA/129 fibrosarcomas and B16F1 melanomas do not elicit a host immune response in wild-type mice and that the asmase-/- phenotype is not deficient in antitumor immunity, supporting the notion that the patterns of tumors growth and radiation response are conditionally linked to the ability of the tumor endothelium to undergo ASMase-mediated apoptosis.

AB - Previous studies provided evidence that MCA/129 fibrosarcomas and B16 melanomas grow 2- to 4-fold faster in acid sphingomyelinase (asmase) - deficient mice than in asmase+/+ littermates and are resistant to single-dose irradiation due to inability to mount an apoptotic response in tumor microvascular endothelium. However, others postulated the differences might be associated with a host antitumor immune response in asmase+/+ mice that is not expressed in asmase-/- mice due to phenotypic deficiency in antitumor immunity. The present studies demonstrate that none of the tumor-host combinations displayed the classic criteria of an immunogenic tumor because they lacked endotumoral or peritumoral infiltrates almost entirely. Furthermore, neither MCA/129 fibrosarcoma nor B16 melanoma tumors showed differences in growth or radioresponsiveness when implanted into mutant mouse models (Rag-/- and MEF-/-) lacking functional immune cell [natural killer (NK), NK-T, T, and B cells] populations. Additionally, development and function of B-, T-, and NK-cell populations in asmase -/- mice were normal, indistinguishable from their wild-type littermates. These data provide definitive evidence that MCA/129 fibrosarcomas and B16F1 melanomas do not elicit a host immune response in wild-type mice and that the asmase-/- phenotype is not deficient in antitumor immunity, supporting the notion that the patterns of tumors growth and radiation response are conditionally linked to the ability of the tumor endothelium to undergo ASMase-mediated apoptosis.

UR - http://www.scopus.com/inward/record.url?scp=8544283077&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=8544283077&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-04-2715

DO - 10.1158/0008-5472.CAN-04-2715

M3 - Article

C2 - 15548696

AN - SCOPUS:8544283077

VL - 64

SP - 8285

EP - 8291

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 22

ER -